You are using an outdated browser. Please upgrade your browser to improve your experience.
New subsidiary to partner with organizations pursuing life-saving cellular therapies
January 22 2016
The National Marrow Donor Program® (NMDP) Be The Match®, the national organization that connects patients with their donor match for a life-saving bone marrow or umbilical cord blood transplant, today announced the formation of Be The Match BioTherapiesSM, a subsidiary that will focus on partnering with organizations pursuing new life-saving treatments in cellular therapy.
For more than 25 years, NMDP/Be The Match has provided services and expertise in the field of cellular therapy through the facilitation of 74,000 transplants. Be The Match BioTherapies will extend these unique capabilities to organizations developing and providing new cellular therapies, enabling these organizations to help critically ill patients who can benefit from these new treatments.
“We have a long-standing commitment to pursuing and providing innovative, life-saving therapies and services,” said Jeffrey Chell, M.D., Chief Executive Officer of NMDP/Be The Match and Be The Match BioTherapies. “We are entering this exciting field as a natural extension of our current mission to save lives. If the services and expertise we’ve built over the course of our history can help patients in new ways, we feel it’s our obligation to help.”
Cellular therapies, including marrow and cord blood transplant, are specialized patient treatments that are made from cells collected from the patient or an adult donor, often used to assist the patient’s immune system. New types of cellular therapies can help patients for whom transplant isn’t an option and address post-transplant issues such as life-threatening infection or relapse. These new therapies will treat patients with blood cancer, solid tumors and other conditions. As more is learned, much more can be done to treat cancer and other critical conditions.
Dr. Chell concluded, “While continuing our unwavering focus on transplantation, we look forward to partnering in this innovative field.”